Inhibitory effect of evodiamine alone and in combination with rosiglitazone on in vitro adipocyte differentiation and in vivo obesity related to diabetes
Inhibitory effect of evodiamine alone and in combination with rosiglitazone on in vitro adipocyte differentiation and in vivo obesity related to diabetes
复制标题
DOI：
10.1038/ijo.2009.223
复制
发表时间：
2010-02-01
影响因子：
4.9
通讯作者：
Cha, J-H
中科院分区：
文献类型：
--
作者：
Bak, E. J.;Park, H. G.;Cha, J-H
目的：吴茱萸碱(Evo)具有抗炎、抗伤害和抗癌等作用。本研究采用3T3-L1和C3H10T1/2细胞，观察Evo单独及与罗格列酮(ROSI)合用对脂肪细胞体外分化和体内肥胖的影响。油红O染色和逆转录聚合酶链式反应(RT-PCR)检测细胞分化程度。4组db/db小鼠分别给予赋形剂、Evo、Rosi和Evo+Rosi，每天1次。结果：在成脂诱导过程中，Evo或Evo与Rosi联合使用对脂肪细胞的分化有明显的抑制作用，尤其是在承诺阶段和诱导早期。Db/db小鼠的evo和evo+rosi组的体重增加明显减少。Evo组小鼠附睾部白色脂肪细胞组织重量与体重的比值也明显降低。值得注意的是，在Evo+ROSI治疗中，血糖水平下降的程度与ROSI组相似，而血浆胰岛素水平的下降明显好于ROSI组。此外，Evo组和Evo+Rosi组与脂肪和糖原沉积相关的肝脏病变在形态上有所改善。结论：Evo对体外脂肪细胞分化和体内肥胖具有抑制作用，并对胰岛素抵抗有改善作用。即使在罗西的存在下，埃沃病毒的这些理想效果也被注意到了。这些结果表明，Evo改善了Rosi的不良作用，包括脂肪生成、体重增加和肝毒性，同时保留了其理想的降血糖作用。《国际肥胖杂志》(2010年)34250260；doi：10.1038/ijo.2009.223；10月27日在线发布
Objective: Evodiamine (evo) has been shown to exert anti-inflammatory, antinociceptive and anticancer effects. In this study, we investigated the effects of evo alone and in combination with rosiglitazone (rosi) on in vitro adipocyte differentiation and in vivo obesity related to diabetes.Methods: Adipocyte differentiation was investigated in vitro using 3T3-L1 and C3H10T1/2 cells. To determine the degree of differentiation, Oil Red O staining and reverse transcription-PCR were carried out. Four groups of db/db mice were treated intraperitoneally once per day with vehicle, evo, rosi and evo + rosi. The mice were killed after 14 days and the blood, liver and adipose tissue were analyzed.Results: The presence of evo or evo combined with rosi during adipogenic induction has been shown to inhibit adipocyte differentiation to a significant degree, particularly at the commitment and early induction stages. The evo and evo + rosi groups of db/db mice evidenced significant reductions in body weight gain. The ratio of epididymal white adipocyte tissue weight to body weight of the evo group was also significantly reduced. It is important to note that in the evo + rosi treatment, blood glucose levels were reduced to a degree similar to that of the rosi group, and plasma insulin levels were reduced significantly better than that of rosi group. Furthermore, hepatic lesions associated with fat and glycogen deposition were morphologically improved in the evo and evo + rosi groups.Conclusion: The results of this study showed that evo exerts an inhibitory effect on in vitro adipocyte differentiation and in vivo obesity, and also an improvement effect on insulin resistance. These desirable effects of evo were noted even in the presence of rosi. These results indicate that evo improves the undesirable effects of rosi, including adipogenesis, body weight gain and hepatotoxicity, while preserving its desirable blood-glucose-lowering effect. International Journal of Obesity (2010) 34, 250-260; doi: 10.1038/ijo.2009.223; published online 27 October 2009